Soluble E-cadherin-CXCL1-CXCR2 axis as a therapeutic vulnerability in inflammatory breast cancer brain metastasis
Neuro-Oncology · 01.05.2026 · 28 (5) · 1220-1236
DOI: 10.1093/neuonc/noag012 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology, online erschienen am 23.01.2026. Verfasst von Xiaoding Hu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Section of Translational Breast Cancer Research, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston. Hauptthemen laut MEDLINE: Receptors, Interleukin-8B, Brain Neoplasms, Inflammatory Breast Neoplasms, Cadherins. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Department of Defense Breast Cancer Research Program, National Institute of Health/National Cancer Institute.
Abstract (Originalsprache)
Background
The brain is a common site of relapse in inflammatory breast cancer (IBC), an E-cadherin-positive, aggressive form of breast cancer. Elevated serum levels of soluble E-cadherin (sEcad), an 80-kDa fragment, correlated with poorer outcomes and increased brain metastases in patients with metastatic IBC. We hypothesize that sEcad is a driver of brain metastasis in IBC.
Methods
Serum sEcad levels from 348 IBC patients were quantified by ELISA. To examine sEcad function, we used recombinant sEcad protein and generated stable IBC cell lines by cloning and overexpressing Flag-tagged sEcad. Control and sEcad-overexpressing MDA-IBC3 and SUM149 cells were injected into SCID/Beige mice to evaluate brain metastasis burden and survival, and a brain-permeable CXCR2 inhibitor was also tested for efficacy in these models.
Results
Higher serum sEcad levels correlated with poorer overall survival, earlier metastasis, and increased brain metastasis. In vitro, recombinant sEcad and stable sEcad overexpression in IBC cell lines promoted invasion, resistance to anoikis, and activation of pro-survival NF-κβ signaling. In vivo, mice injected with sEcad-overexpressing IBC cells had increased metastatic burden and reduced overall and brain metastasis-free survival. Further, sEcad induced reactive astrocytosis through the CXCL1/CXCL8-CXCR2 axis, and treatment with a brain-permeable CXCR2 antagonist reduced metastatic burden and prolonged survival in the brain metastasis models. Conclusion sEcad drives brain metastasis by promoting invasion and anoikis resistance in cancer cells and inducing an inflammatory brain microenvironment via a targetable CXCL1/CXCL8-CXCR2 axis. These findings uncover a novel and critical role for sEcad and highlight CXCR2 as a therapeutic target in patients with metastatic IBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Section of Translational Breast Cancer Research, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston.
- MD Anderson Morgan Welch Inflammatory Breast Cancer Clinic and Research Program, The University of Texas MD Anderson Cancer Center, Houston.
- Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston.
- Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston.
- Department of Veterinary Medicine and Surgery, The University of Texas MD Anderson Cancer Center, Houston.
- Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston.
ORCID-Profile: Xiaoding Hu, Juhee Song, Wendy A Woodward, Junjie Chen, Bisrat G Debeb
Förderung
- NCI NIH HHS
- Department of Defense Breast Cancer Research Program
- National Institute of Health/National Cancer Institute
- American Cancer Society
- Anderson Cancer Center
- NIH/NCI Cancer Center Support
Zitieren
APA
Hu, X., Xiong, Y., Villodre, E. S., Zhang, H., Longa, I. R., Song, J., Fowlkes, N., Krishnamurthy, S., Rylander, M., Bartholomeusz, C., Tripathy, D., Woodward, W. A., Chen, J., & Debeb, B. G. (2026). Soluble E-cadherin-CXCL1-CXCR2 axis as a therapeutic vulnerability in inflammatory breast cancer brain metastasis. Neuro-Oncology, 28(5), 1220-1236. https://doi.org/10.1093/neuonc/noag012
Vancouver
Hu X, Xiong Y, Villodre ES, Zhang H, Longa IR, Song J, et al. Soluble E-cadherin-CXCL1-CXCR2 axis as a therapeutic vulnerability in inflammatory breast cancer brain metastasis. Neuro-Oncology. 2026;28(5):1220-1236. doi:10.1093/neuonc/noag012
BibTeX
@article{Hu2026,
author = {Hu, Xiaoding and Xiong, Yun and Villodre, Emilly S and Zhang, Huimin and Longa, Isabella R and Song, Juhee and Fowlkes, Natalie and Krishnamurthy, Savitri and Rylander, Marissa and Bartholomeusz, Chandra and Tripathy, Debu and Woodward, Wendy A and Chen, Junjie and Debeb, Bisrat G},
title = {Soluble E-cadherin-CXCL1-CXCR2 axis as a therapeutic vulnerability in inflammatory breast cancer brain metastasis},
journal = {Neuro-Oncology},
year = {2026},
volume = {28},
number = {5},
pages = {1220--1236},
doi = {10.1093/neuonc/noag012}
}
EUVIMED